Isotechnika Pharma appoints Dr. Jurgen Engel to Board of Directors



    EDMONTON, Aug. 13 /CNW/ - Isotechnika Pharma Inc. (TSX:ISA) today
announced that it has appointed Dr. Jurgen Engel to its Board of Directors.
Dr. Engel is currently the President and CEO of AEterna Zentaris, where he has
been since the acquisition of Zentaris in December 2002. A seasoned
professional in the pharmaceutical industry, he brings extensive expertise in
drug development and commercialization and partnership development. Prior to
AEterna Zentaris he was CEO of Zentaris, a spin-off of ASTA Medica, AG, where
he oversaw all Research and Development activities, supervised more than 700
scientists and clinical professionals, and successfully headed projects from
drug discoveries to New Drug Applications.
    "Dr. Engel has a proven track record and extensive background in the
pharmaceutical industry," stated Dr. Robert Foster, President & CEO of
Isotechnika. "His wealth of experience will provide us with knowledgeable
counsel and guidance as we put more focus on in-licensing to build our
pipeline, while continuing to focus on the commercialization of voclosporin in
the U.S., Europe and Asia."
    Dr. Engel earned a doctorate degree in organic chemistry from the
Technical University of Braunschweig, as well as an academic degree in
pharmaceutical science from the University of Regensburg, where he is also a
professor. In 1995, he was recognized for his development of
alkylphospholipids as a new class of anti-tumor agents by receiving the
Galenus-von-Pergamon Prize, an award that honors innovators in novel
medicines.

    
    About Isotechnika
    -----------------
    

    Edmonton-based Isotechnika Pharma Inc. is a biopharmaceutical company
focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential will exceed $4 billion annually in sales
for calcineurin inhibitors such as voclosporin by 2010.
    Voclosporin is a next generation calcineurin inhibitor, which completed a
Phase 2b North American trial for the prevention of kidney rejection following
transplantation. Extensions to the Phase 2b trial and a combined Phase 3
European/Canadian trial for the treatment of moderate to severe psoriasis have
also been completed. Our partner, Lux BioSciences, Inc., has also completed
three separate Phase 2/3 pivotal trials investigating voclosporin (referred to
as LUVENIQ(TM) by Lux) for the treatment of uveitis. In addition to the
uveitis trials, Lux BioSciences Inc. has also commenced a Phase 1 trial using
their proprietary voclosporin ophthalmic solution (LX214) as a candidate for
dry eye syndrome. Voclosporin has also entered First-in-Man trials as the drug
utilized in the CINATRA(TM) Drug Coated Coronary Stent system developed by the
Company's partner, Atrium Medical Corporation.
    Isotechnika Pharma Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika Pharma can be
found at www.isotechnika.com or www.SEDAR.com.

    
    Forward-Looking Statements
    --------------------------
    
    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its intellectual property rights from
infringement by third parties, and the risk that the Company's intellectual
property rights may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly and annual
filings with the Canadian commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements.

    %SEDAR: 00010508E




For further information:

For further information: Dr. Robert Foster, President & CEO, Isotechnika
Pharma Inc., (780) 487-1600 (247), (780) 484-4105 (fax),
rfoster@isotechnika.com; Mr. Dennis Bourgeault, Chief Financial Officer,
Isotechnika Pharma Inc., (780) 487-1600 (226), (780) 484-4105 (fax),
dbourgeault@isotechnika.com

Organization Profile

ISOTECHNIKA PHARMA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890